GLP-1 medications improve insulin sensitivity and reduce visceral fat, hence, directly addressing the metabolic drivers of PCOS/PMOS, not just appetite
Only after comprehensive individual safety and efficacy profiles are established, and specific mechanisms of action are fully elucidated, can well-designed studies begin to explore potential synergistic combinations
The new pill joins drugmaker Novo Nordisk's oral Wegovy pill, which has spurred more than 600,000 prescriptions in the United States since it was approved in December
You can compare Harbor's semaglutide and tirzepatide programs to see how the two options stack up side by side
(Im not saying this is an important goal for all, but it matters to some people.) These drugs are intended for people who need to lose a fair amount of weight and for whom that would make a significant improvement in their health outcomes